Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RLMD · NASDAQ · Pharmaceutical Preparations
Relmada Therapeutics (RLMD) · oqro.io/stocks/RLMD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.21+0.05 (+1.20%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Traded Aug 26 – Aug 28, 2025 · largest single transaction ~$87K
Aug 27, 2025~$87K · 129K sh @ $0.67
DetailsOfficial recordAug 26, 2025~$50K · 81K sh @ $0.62
DetailsOfficial recordAug 28, 2025~$41K · 56K sh @ $0.74
DetailsOfficial recordTraded May 16 – May 20, 2025 · largest single transaction ~$82K
May 20, 2025~$82K · 148K sh @ $0.5569
DetailsOfficial recordTraded May 16 – May 20, 2025 · largest single transaction ~$44K
May 19, 2025~$44K · 90K sh @ $0.4854
DetailsOfficial recordInsider buying
Traded May 16, 2025 · filed 4 days later
Since the trade +813.2% · S&P 500 +27.0% · to Nov 13
A Relmada Therapeutics director paid $86K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 94% with this purchase.
Insider buying
Traded May 16, 2025 · filed 4 days later
Since the trade +813.2% · S&P 500 +27.0% · to Nov 13
Relmada Therapeutics's CA and CO paid $103K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 588% with this purchase.
May 16, 2025~$77K · 172K sh @ $0.4496
DetailsOfficial recordMay 19, 2025~$15K · 30K sh @ $0.4998
DetailsOfficial recordMay 20, 2025~$31K · 60K sh @ $0.5237
DetailsOfficial recordMay 16, 2025~$22K · 50K sh @ $0.442
DetailsOfficial record0 open-market purchases and 0 open-market sales by insiders of RLMD between Feb 18, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 12, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 12, 2026 | None | None | None |
| Aug 6, 2026 | None | None | None |
| May 12, 2026 | None | None | None |
| Mar 20, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
